The Genmab A/S (GMAB) shares are trading at higher $32.59 and the avg recommendation for the stock is Strong Buy. The current analyst price target stands at $34.50.
To add more color to this target, the company’s high over the last year is $32.11 and the low is $16.24. Over the last 52 weeks, GMAB is up 1.49% while the S&P 500 is up 0.64%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, GMAB reported a profit of $121.26 million. Genmab A/S also saw revenues increase to $131.75 million. In addition, GMAB has free cash flow of $323.76 million as of 03-2020 The company’s EBITDA came in at $10.49 million which compares well with its peers.
Find out when GMAB reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. GMAB has a short ratio of 0.84 and outstanding shares of 651.16M.
GMAB has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.09 million and more growth is possible in the weeks ahead. Investors should also keep an eye on sector updates as GMAB has historically followed its peers on positive news.
All told, Genmab A/S GMAB has strung together solid data and demonstrated underlying fundamentals. At its current valuation, GMAB represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Genmab A/S GMAB is now commanding a market cap of 21.22B and a float of 642.65M. GMAB is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of GMAB stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in GMAB, either long or short, and we have not been compensated for this article.